The implementation in 2015 of the recent reforms to the PBS Access and Sustainability Package has led to significant changes in the cost of drugs to the government. These changes have kept the PBS affordable and fiscally sustainable in the future. Access to medicines for Australian consumers in the health sector is supported by the National Medicines Policy adopted in 1999. The National Medicines Policy has four central objectives: “Every time a patient or healthcare professional uses a generic drug or biosimilar, they save money that can be used to pay for recent PBS drugs. GMiA members have and continue to provide billions of dollars in PBS savings,” said Mark Crotty, President of GMiA (2015). The Commission`s reference to New Zealand`s pharmaceutical system ignores the shortcomings of that country`s tendering system, which include restrictions on the selection of medicines by patients and doctors, as well as the risk of drug shortages due to the dependence of each supplier. It is of little use in the report using as an example a single comparison of medicines, which contains outdated prices and does not recognise the lack of choice. The Generic Medicines Industry Association (GMiA) has signed a strategic agreement with the Australian government to support the supply of affordable generic and biosimilar products in Australia and to ensure five years of security for the industry it provides. This agreement has been extended for a further two years. The extension document can be consulted at the bottom of this page. …

with price disclosure that provides lower prices and prescription quantities are well controlled. “Many of us here today personally owe our health and productivity to PBS-subsidized drugs, and we all have family, friends and constituents who rely on the program to get the drugs they need.” GMiA and the government have a common interest in continued and reliable access to affordable generic and biosimilar medicines, a strong PBS capable of meeting the current and future needs of Australians and a sustainable generic medicines sector,” he said. The 2016-2017 federal budget confirms that the Pharmaceutical Benefits Scheme is stable and will continue to ensure, after years of significant reforms in this sector, that Australian patients have access to safe and effective medicines. The latest study on the effects of large increases in the contribution concluded that the increase in patient contributions has a particular impact on the ability of patients in concession to afford medicines. This is an impact that should be of interest to policymakers. The agreement states that there will be no further changes to the F2 formula based on prices and that the Department of Health and the GMiA will work together to quickly identify and resolve the unintended consequences of budget savings, particularly where they may impact the reliability of essential and affordable medicine care for Australian patients. These enhancements support the shared commitment to improve the transparency, timeliness and efficiency of PBS information processes. The changes will ensure that Australians continue to have access to needed medicines in a timely and affordable manner. The recent significant increase in premiums was a 24 per cent increase in both supplements with effect from 1 January 2005. A large study from the University of Western Australia showed that compared to samples before the premium increase, prescriptions for combined athmatism drugs decreased by 8%, for proton pump inhibitors and by 5% for statins. . .

.

Strategic Agreement With Medicines Australia

  • October 9th, 2021
  • Posted in Uncategorized

Comments are closed.